Kasumi Kikuchi, None;
Kousuke Noda, Alcon Pharma Co. Ltd. (F), Coopervision Inc. (F), Mitsubishi Tanabe Pharma Corp. (F), NIDEK Co., Ltd. (P), Novartis Pharma, K.K. (F), Otsuka Pharmaceutical Co., Ltd. (F), SEED Co., Ltd. (P), Senju Pharmaceutical Co., Ltd. (P), Sucampo Pharma, LLC. (F);
Miyuki Murata, None;
Yoshiaki Tagawa, None;
Atsuhiro Kanda, Alcon Pharma Co. Ltd. (F), Bayer Yakuhin, Ltd. (F), Bonac Co., Ltd. (P), Novartis Pharma, K.K. (F), SEED Co., Ltd. (P), Senju Pharmaceutical Co., Ltd. (P);
Satoru Kase, ROHTO Pharmaceutical Co., Ltd. (F);
Yasushi Kageyama, CLEA Japan Inc. (E);
Masami Shinohara, CLEA Japan Inc. (E);
Tomohiko Sasase, Japan Tobacco Inc. (E);
Susumu Ishida, Alcon Japan Ltd (F), AMO Japan K.K. (F), Bayer Yakuhin, Ltd. (F), Bonac Co., Ltd. (P), Chugai Pharmaceutical Co., Ltd. (P), Kowa Pharmaceutical Co., Ltd. (F), NIDEK Co., Ltd. (F), NIDEK Co., Ltd. (P), Novartis Pharma, K.K. (F), Otsuka Pharmaceutical Co., Ltd. (F), Santen Pharmaceutical Co., Ltd. (F), SEED Co., Ltd. (P), SEED Co., Ltd. (F), Senju Pharmaceutical Co., Ltd. (P), Senju Pharmaceutical Co., Ltd. (F), Takeyama Co., Ltd. (F), Wakamoto Pharmaceutical Co., Ltd. (F), White Medical Co.,Ltd. (F)